Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174336 · ClinicalTrials.gov registry record · Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Phase 3 study of Breast Neoplasms and Neoplasm Metastasis, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 920
- Enrollment target
- 20
- Study locations
NCT07174336 is a Phase 3 study of Breast Neoplasms and Neoplasm Metastasis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 920 participants, above the 560-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (64% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07174336, a Phase 3 study of Breast Neoplasms and Neoplasm Metastasis, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 920 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribociclib
- DRUG LY4064809
Study Locations (20)
California
- City of Hope - Duarte
- Marin Cancer Care - Greenbrae
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine - Irvine
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- Moores Cancer Center - La Jolla
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Kaiser Permanente Oakland - Oakland
- Profound Research LLC - Oceanside
- University of California, Irvine (UCI) Health - UC Irvine Medical Center - Orange
- Desert Regional Medical Center - Palm Springs
- Stanford Cancer Center - Palo Alto
- Kaiser Permanente - Roseville
- Kaiser Permanente - San Francisco
- UCSF Medical Center at Mission Bay - San Francisco
Arizona
- Ironwood Cancer & Research Centers - Chandler
- Mayo Clinic in Arizona - Phoenix - Phoenix
- The University of Arizona Cancer Center - North Campus - Tucson
Alaska
- Alaska Oncology and Hematology - Anchorage
Arkansas
- Highlands Oncology Group - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 920 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2033-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07174336
The ClinicalTrials.gov registry entry for NCT07174336 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 920 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 560-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (64% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT07174336 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alaska.
Frequently Asked Questions
What is clinical trial NCT07174336 about?
NCT07174336 is a clinical study titled "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)". The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain ...
What is the current status of trial NCT07174336?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 920 participants. The study started on 2025-12-22. Estimated completion is 2033-05.
What conditions does trial NCT07174336 study?
This clinical trial studies the following conditions: Breast Neoplasms, Neoplasm Metastasis.
What interventions are being tested in trial NCT07174336?
The interventions under investigation include: Placebo (DRUG), Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG), LY4064809 (DRUG).
Who is sponsoring clinical trial NCT07174336?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174336 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RECRUITING · Phase 3
-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RECRUITING · Phase 3
-
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RECRUITING · Phase 3
-
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.